MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers raised its position in MeiraGTx Holdings plc (NASDAQ:MGTX) by 12.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,891 shares of the company’s stock after acquiring an additional 5,993 shares during the quarter. Rhumbline Advisers’ holdings in MeiraGTx were worth $334,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Knoll Capital Management LLC purchased a new position in MeiraGTx in the 3rd quarter valued at about $5,212,000. Erste Asset Management GmbH purchased a new position in MeiraGTx in the third quarter valued at about $2,795,000. Garden State Investment Advisory Services LLC purchased a new position in MeiraGTx in the third quarter valued at about $1,636,000. Barclays PLC grew its stake in MeiraGTx by 107.1% during the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock valued at $618,000 after purchasing an additional 76,437 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new stake in MeiraGTx during the 4th quarter worth approximately $459,000. Hedge funds and other institutional investors own 67.48% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on MGTX shares. Chardan Capital reiterated a “buy” rating and set a $36.00 price objective on shares of MeiraGTx in a research note on Monday, February 24th. Royal Bank of Canada increased their price target on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th.

MeiraGTx Price Performance

NASDAQ MGTX opened at $6.38 on Monday. The company has a 50-day moving average price of $6.46 and a two-hundred day moving average price of $5.73. MeiraGTx Holdings plc has a 52 week low of $3.85 and a 52 week high of $7.80. The stock has a market cap of $498.62 million, a price-to-earnings ratio of -5.27, a price-to-earnings-growth ratio of 0.37 and a beta of 1.23. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86.

Insider Buying and Selling at MeiraGTx

In related news, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total value of $150,960.00. Following the sale, the chief financial officer now directly owns 849,947 shares in the company, valued at $5,346,166.63. The trade was a 2.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Alexandria Forbes sold 35,839 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total value of $231,878.33. Following the completion of the transaction, the chief executive officer now directly owns 1,395,102 shares in the company, valued at $9,026,309.94. This represents a 2.50 % decrease in their position. The disclosure for this sale can be found here. 8.40% of the stock is owned by corporate insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.